摘要
目的研究慢性肾炎患者实施缬沙坦联合黄葵胶囊治疗的效果。方法选取2022年1—12月菏泽市牡丹人民医院慢性肾炎患者60例为研究对象,采用随机数字表法分为试验组(n=30)和对照组(n=30)。试验组患者实施缬沙坦联合黄葵胶囊治疗,对照组患者实施缬沙坦治疗。对比干预后2组患者的肾功能指标水平、24 h尿蛋白定量、尿白蛋白与肌酐比值(urinary albumin to creatinine ratio,UACR)以及治疗总有效率。结果干预后,试验组血尿素氮(blood urea nitrogen,BUN)、尿酸(uric acid,UA)水平分别为(5.05±0.61)mmol/L、(254.59±8.90)μmol/L,低于对照组的(6.44±0.42)mmol/L、(307.77±10.86)μmol/L,试验组估算肾小球滤过率(estimated glomerular filtration rate,eGFR)为(100.57±1.85)mL/(min·1.73 m^(2)),高于对照组的(97.29±1.73)mL/(min·1.73 m^(2)),差异有统计学意义(P<0.001);试验组24 h尿蛋白定量、UACR分别为(113.94±4.20)mg/24 h、(24.77±1.74)mg/g,低于对照组的(130.43±5.08)mg/24 h、(28.62±1.88)mg/g,差异有统计学意义(P<0.001);试验组治疗总有效率为96.67%,高于对照组的73.33%,差异有统计学意义(P<0.05)。结论慢性肾炎患者使用缬沙坦联合黄葵胶囊进行治疗,可以有效改善肾功能水平及预后,降低24 h尿蛋白水平,效果显著。
Objective To study the efficacy of valsartan combined with Huangkui capsules in the treatment of patients with chronic nephritis.Methods A tatal of 60 patients with chronic nephritis in Mudan People's Hospital,Heze City from January to December 2022 were selected as the research subjects and divided into the experimental group(n=30)and the control group(n=30)by random number table method.Patients in the experimental group were treated with valsartan combined with Huangkui capsules,while those in the control group were treated with valsartan.The levels of renal function indicators,24-hour urine protein quantification,urinary albumin to creatinine ratio(UACR)and the total effective rate of treatment of the two groups of patients after the intervention were compared.Results After the intervention,the levels of blood urea nitrogen(BUN),and uric acid(UA)in the experimental group were(5.05±0.61)mmol/L and(254.59±8.90)μmol/L respectively,which were significantly lower than those in the control group[(6.44±0.42)mmol/L and(307.77±10.86)μmol/L],the estimated glomerular filtration rate(eGFR)in the experimental group was(100.57±1.85)mL/(min·1.73 m^(2)),significantly higher than that in the control group[(97.29±1.73)mL/(min·1.73 m^(2))],and the differences were statistically significant(P<0.001).The 24-hour urine protein quantification and UACR of the experimental group were(113.94±4.20)mg/24 h and(24.77±1.74)mg/g respectively,which were lower than those of the control group[(130.43±5.08)mg/24 h and(28.62±1.88)mg/g],and the differences were statistically significant(P<0.001).The total effective rate of the experimental group was 96.67%,which was higher than that of the control group(73.33%),and the difference was statistically significant(P<0.05).Conclusion The treatment of patients with chronic nephritis using valsartan combined with Huangkui capsules can effectively improve the renal function level and prognosis,and reduce the 24-hour urine protein level,with significant effects.
作者
陈红军
王琳
李亚
CHEN Hongjun;WANG Lin;LI Ya(Department of Nephrology,Mudan People's Hospital,Heze City,Heze Shandong 274000,China)
出处
《中国卫生标准管理》
2025年第13期146-149,共4页
China Health Standard Management
关键词
缬沙坦
黄葵胶囊
疗效
慢性肾炎
肾功能
治疗方案
valsartan
Huangkui capsules
therapeutic efficacy
chronic nephritis
renal function
treatment plan
